

*The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



天津泰達生物醫學工程股份有限公司  
**Tianjin TEDA Biomedical Engineering Company Limited**  
*(a joint stock company incorporated in the People's Republic of China with limited liability)*  
(Stock code: 8189)

## **PROFIT WARNING**

This announcement is made pursuant to Rule 17.10(2)(a) of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the “**GEM Listing Rules**”) and the Inside Information Provisions (as defined under the GEM Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of Tianjin TEDA Biomedical Engineering Company Limited (the “**Company**”) wishes to inform the shareholders of the Company and potential investors that, based on the information currently available, including but not limited to the consolidated results of the Company and its subsidiaries (collectively, the “**Group**”), the Group is expected to incur a loss attributable to shareholders of approximately RMB85.00 million for the year ended 31 December 2025 as compared with the loss attributable to shareholders of RMB27,802,241 for the year ended 31 December 2024.

The expansion of the expected loss is primarily attributable to the continued pressure on the operating environment of the compound fertilizer industry in 2025, coupled with volatility at high levels in the prices of key raw materials such as urea, ammonium phosphate, potash, and sulfur. This is further compounded by geopolitical tensions in the Middle East with heightened volatility in the global raw material supply chain, and the market expects raw material prices to remain relatively high in the near future. Overall demand in the compound fertilizer industry remains weak, market competition is intensifying, product prices are struggling to keep pace with inflation, and profit margins continue to be squeezed; consequently, the valuation of plant and land assets used for compound fertilizer production is under pressure. Taking into account the market conditions and the actual status of the assets, the Group conducted a prudent assessment of assets related to its fertilizer business, including accounts receivable, prepayments, fixed assets, and plant and land. Provisions for the allowances of related assets increased significantly this year as compared to last year, which collectively impacted the financial performance for the year.

The Company is still in the process of finalising the annual results of the Group. The information contained in this announcement is only based on the preliminary assessment by the Board according to the estimated annual results of the Group and, therefore, the audited annual results may differ from the data contained in this announcement. Details of the annual results will be published by the end of March 2026.

Shareholders and potential investors of the Company are urged to exercise caution when dealing in the shares of the Company.

By order of the Board  
**Tianjin TEDA Biomedical Engineering Company Limited**  
**Sun Li**  
*Chairman*

Tianjin, the PRC  
29 March 2026

*As at the date of this announcement, the executive directors of the Company are Ms. Sun Li, Mr. Yang Zeng and Mr. Xia Alan Zhe; the non-executive directors of the Company are Mr. He Xin, Dr. Li Ximing and Mr. Wang Lei; the independent non-executive directors of the Company are Ms. Gao Chun, Mr. Tu Xiangzhen and Mr. Chen Jiang.*

*This announcement, for which the directors are willing to collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The directors of the Company, having made all reasonable enquiries, confirm that to the best of their knowledge and belief that the data contained in this announcement is accurate and complete in all material respects and is not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the GEM website at <http://www.hkgem.com> on the “Latest Listed Company Information” page for 7 days from the date of its posting, and it will also be published and remain on the website of the Company at [www.bioteda.com](http://www.bioteda.com).*